Health and Fitness

After Lisa Marie Presley died on January 12, headlines swirled about cardiac arrest being the potential cause of her death. Now the Los Angeles County Medical Examiner has delivered a sobering update: Presley died of small bowel obstruction, which developed due to scar tissue that formed after she had bariatric surgery, a term that encompasses …

Lisa Marie Presley Died of Small Bowel Obstruction—Here’s What That Means Read More »

Let’s get real for a second: The world of wearables can be pretty intimidating. Technology in this category has evolved rapidly, meaning there are so many options to choose from, featuring all kinds of metrics. (HRV! Sleep score! Recovery!) In order to cut through the noise, we scored advice from experts on the best fitness …

10 Best Fitness Trackers, According to Experts in 2023 Read More »

If you notice any of the signs above, the below tips may help you establish a healthier dynamic with your watch. At any time though, if you feel like you need additional support, seek help from a mental health professional, says Brauer. How to improve your relationship with your fitness tracker Mending your relationship with …

How to Use a Fitness Tracker Without Letting It Rule Your Life Read More »

Sure, you might love your eyebrows, say, or your long legs, but try to also think about qualities that aren’t so tied to what’s on the outside (because even fixating on your favorite physical traits is just another way to attach your value to your appearance). Instead, you might scribble something like, “I don’t look …

How to Stop Comparing Your Current Body to Your Former One Read More »

If you have migraine, you probably know the signs of an attack all too well: A throbbing headache, nausea, and sensitivity to certain lights and sounds can be hell. But you might also notice that you feel off in the days or hours leading up to an attack. Maybe you’re uncharacteristically irritable, guzzling more water …

What to Know About Prodrome Migraine Symptoms, According to Experts Read More »

Berlin, June 3, 2022, – Bayer will present new renal and cardiovascular data from the comprehensive Kerendia™ (finerenone) clinical trial program at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions. This new data will comprise of further insights from FIDELITY, including late-breaking data from a new post-hoc analysis, as well as retrospective findings from …

Bayer to present new Kerendia™ (finerenone) data from comprehensive clinical trial program across a broad range of patients with chronic kidney disease and type 2 diabetes Read More »

CAMBRIDGE, Mass., May 31, 2022 – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). The purpose of the Ph1 clinical trial is to evaluate the …

BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson’s Disease Read More »

Monheim, Germany, May 24, 2022 – Joining like-minded companies in the private sector, Bayer has signed the Zero Hunger Private Sector Pledge with a 160 million U.S. dollar commitment dedicated to help end global hunger. The Pledge, in the context of the UN Food Systems Summit of 2021 and as a part of the Summit’s …

Bayer makes 160 million U.S. dollar commitment to Zero Hunger Pledge Read More »

Berlin, May 23, 2022 – Two studies with Bayer´s Factor Xa inhibitor rivaroxaban (Xarelto), the Long-Term Open Label Extension (LTOLE) of the COMPASS trial and the XATOA registry, provide complementary evidence of the benefits of dual pathway inhibition (DPI), defined as the combination of the vascular dose of Xarelto(2.5 mg twice daily) and aspirin. The …

Two large Xarelto™ studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease Read More »

Berlin, May 23, 2022 – Late-breaking data from an exploratory post hoc analysis from FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD trials, reinforce the renal and cardiovascular (CV) benefits of Kerendia (finerenone), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. Data from the analysis indicate that compared to placebo, Kerendia consistently …

New data support renal and cardiovascular benefits of Kerendia™ (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes Read More »